CRUSH ReportsCRUSH Alerts 2.0CRUSH Industry ReportsCRUSHarmyContact Manager ApplicationMid-Market Manager ApplicationTarget Builder Application
 

st. Jude Medical (sTJ)

The st. Jude Medical CRUSH Report is a Fortune 1000 deep dive sales intelligence company profile and will help increase your sales leads and add more accounts in your sales pipeline while eliminating costly research time.

The st. Jude Medical CRUSH Report contains insights to IT architectures, business and technology initiatives, corporate strategies, projects and budgets, org charts and key decision-maker contact info.

The st. Jude Medical CRUSH Report allows IT sales and marketing professionals to:
  • Jump-start sales cycles in net new accounts
  • Expand footprints in existing customer accounts
  • Facilitate the strategic account planning process
  • Respond to RFPs & bids more effectively
  • Build better content into executive level presentations
  • Identify the presence of competitors & partners
The st. Jude Medical CRUSH Report has the competitive intelligence needed for account planning within the Fortune 1000. Target the right people, with the right message at the right time using our org charts, decision maker contact info, business drivers and IT landscapes.

Click here to download free sample CRUSH Reports

St. Jude Medical, Inc. News Release

A Collection of St. Jude Medical, Inc. News Release

Key Clinical Data for St. Jude Medical’s Structural Heart Technologies Revealed at EuroPCR
Wednesday May 16th 2012 06:31:00 AM

ST. PAUL, Minn. & PARIS--(BUSINESS WIRE)--May. 16, 2012-- St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced that significant clinical data for its structural heart portfolio is being presented during EuroPCR. Among the highlights are first-in-man and six-month data for the company’s Portico™ Transcatheter Aortic Heart Valve and results from a multicenter study for AMPLATZER™ Cardiac Plug (ACP) technology. St. Jude Medical’s Transcatheter Aortic Valve Implantation (TAVI) Technology Information about the St. Jude Medical Portico valve will be presented during a Glimps...

Blinklist Blogmarks del.icio.us Digg Ma.gnolia My Web 2.0 Newsvine Reddit Segnalo Simpy Spurl Wists Technorati

Renal Denervation Technology from St. Jude Medical Demonstrates Significant Reduction in Blood Pressure
Wednesday May 16th 2012 02:47:41 AM

Use of EnligHTN technology resulted in a 28 point reduction of systolic blood pressure on average after 1 month Trial showed double the reduction in blood pressure of competitive technology in the same timeframe ST. PAUL, Minn. & PARIS--(BUSINESS WIRE)--May. 16, 2012-- St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced that preliminary data demonstrated the company’s EnligHTN™ renal denervation system was safe and effective for the treatment of resistant hypertension. The study demonstrated that on average patients with resistant hypertension experience a systolic b...

Blinklist Blogmarks del.icio.us Digg Ma.gnolia My Web 2.0 Newsvine Reddit Segnalo Simpy Spurl Wists Technorati

FAME II Trial Demonstrates FFR-Guided PCI Superior to Medical Treatment in Preliminary Findings
Tuesday May 15th 2012 09:17:14 AM

St. Jude Medical PressureWire helped reduce the risk of urgent revascularization by more than eleven times in patients with stable coronary artery disease compared to medical treatment alone ST. PAUL, Minn. & PARIS--(BUSINESS WIRE)--May. 15, 2012-- St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced that data from the FAME II trial demonstrated a significant difference in the need for urgent revascularization when Fractional Flow Reserve (FFR)-guided assessment was used to direct treatment in patients with stable coronary artery disease. These highly statistically significant result...

Blinklist Blogmarks del.icio.us Digg Ma.gnolia My Web 2.0 Newsvine Reddit Segnalo Simpy Spurl Wists Technorati

St. Jude Medical Announces European Approval and Launch of the EnligHTN Renal Denervation System for Treatment of Hypertension
Tuesday May 15th 2012 01:31:00 AM

Decades of experience in ablation technologies used to develop the industry’s first multi-electrode technology for renal denervation ST. PAUL, Minn. & PARIS--(BUSINESS WIRE)--May. 15, 2012-- St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced CE Mark Approval and launch of its EnligHTN™ renal denervation system during EuroPCR. Renal denervation is a specialized ablation procedure that has been clinically proven to reduce blood pressure in patients with hypertension, or high blood pressure, that is resistant to medical therapy. Clinical data from the EnligHTN I trial about the safety and...

Blinklist Blogmarks del.icio.us Digg Ma.gnolia My Web 2.0 Newsvine Reddit Segnalo Simpy Spurl Wists Technorati

St. Jude Medical Continues Strong Show of PCI Optimization Technologies at EuroPCR
Monday May 14th 2012 08:01:01 AM

New technology, symposia and a FAME II data presentation keep St. Jude Medical at the forefront of PCI Optimization ST. PAUL, Minn. & PARIS--(BUSINESS WIRE)--May. 14, 2012-- St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced it will display a number of technologies from the company's wide array of clinical solutions and launch its next-generation PressureWire™ Fractional Flow Reserve (FFR) assessment guidewire at EuroPCR 2012. There will also be a number of St. Jude Medical-sponsored percutaneous coronary intervention (PCI) optimization symposia and a late-breaking clinical trial s...

Blinklist Blogmarks del.icio.us Digg Ma.gnolia My Web 2.0 Newsvine Reddit Segnalo Simpy Spurl Wists Technorati

St. Jude Medical Announces Results of SCD-HeFT 10-Year Follow-up Study
Thursday May 10th 2012 04:21:22 PM

Study confirms ICD therapy improves long-term survival of patients with heart failure ST. PAUL, Minn.--(BUSINESS WIRE)--May. 10, 2012-- St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced results of the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial) 10-Year Follow-up Study at Heart Rhythm 2012, the Heart Rhythm Society's 33rd Annual Scientific Sessions in Boston. The study demonstrated implantable cardioverter defibrillator (ICD) therapy significantly reduces mortality for at least 11 years in patients with moderate heart failure (HF). The SCD-HeFT 10-Year Follow-...

Blinklist Blogmarks del.icio.us Digg Ma.gnolia My Web 2.0 Newsvine Reddit Segnalo Simpy Spurl Wists Technorati

St. Jude Medical Announces FDA Approval of Smaller ICD with Physician Inspired Shape
Wednesday May 9th 2012 08:00:30 AM

Industry’s smallest high-energy device inspired by input from hundreds of physicians ST. PAUL, Minn.--(BUSINESS WIRE)--May. 9, 2012-- St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced U.S. Food and Drug Administration (FDA) approval of its Ellipse™ implantable cardioverter defibrillator (ICD). Designed with feedback from more than 200 physicians from around the world, the Ellipse ICD offers physicians unique design advancements, resulting in the industry’s smallest high-energy ICD. St. Jude Medical Ellipse(TM) ICD (Photo: St. Jude Medical) The Ellipse ICD’s unique...

Blinklist Blogmarks del.icio.us Digg Ma.gnolia My Web 2.0 Newsvine Reddit Segnalo Simpy Spurl Wists Technorati

St. Jude Medical Announces FDA Approval of Assura™ Implantable Defibrillators with Features That Reduce Inappropriate Shocks
Tuesday May 8th 2012 08:01:00 AM

ST. PAUL, Minn.--(BUSINESS WIRE)--May 8, 2012-- St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced U.S. Food and Drug Administration (FDA) approval of its Assura™ portfolio of implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy defibrillators (CRT-Ds). The new implantable defibrillators feature SecureSense™ RV Lead Noise Discrimination, an algorithm that expands the St. Jude Medical ShockGuard® Technology and offers advanced sensing options designed to reduce the incidence of inappropriate shocks for patients with these devices. "The Assura product portfolio offers new features that protect patients from unnecessary defibril...

Blinklist Blogmarks del.icio.us Digg Ma.gnolia My Web 2.0 Newsvine Reddit Segnalo Simpy Spurl Wists Technorati

St. Jude Medical to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
Friday May 4th 2012 09:15:00 AM

ST. PAUL, Minn.--(BUSINESS WIRE)--May 4, 2012-- St. Jude Medical, Inc. (NYSE:STJ) will present at the Bank of America Merrill Lynch 2012 Health Care Conference on Thursday, May 17, in Las Vegas. John Heinmiller, executive vice president and chief financial officer, will address the conference at 9:20 a.m. PDT. The presentation will also be webcast live at http://www.sjm.com. About St. Jude Medical St. Jude Medical, Inc. develops medical technology and services that focus on putting more control into the hands of those who treat cardiac, neurological and chronic pain patients worldwide. The company is dedicated to advancing the practice of medicine by reducing risk wherever possible and c...

Blinklist Blogmarks del.icio.us Digg Ma.gnolia My Web 2.0 Newsvine Reddit Segnalo Simpy Spurl Wists Technorati

St. Jude Medical Announces Second Quarter Dividend
Wednesday May 2nd 2012 10:37:00 PM

Board declares second quarter dividend of $0.23 per share ST. PAUL, Minn.--(BUSINESS WIRE)--May 2, 2012-- St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced that its Board of Directors declared a second quarter dividend of $0.23 per common share. This dividend amount is equal to the dividend paid during the first quarter of 2012 and brings the total dividend declared for the year to $0.46 per share. The dividend is payable July 31, 2012, to shareholders of record on June 29, 2012. About St. Jude Medical St. Jude Medical develops medical technology and services that focus on putting more control into the hands of those who treat cardiac, neurological and...

Blinklist Blogmarks del.icio.us Digg Ma.gnolia My Web 2.0 Newsvine Reddit Segnalo Simpy Spurl Wists Technorati

Decision Chain
Org Charts


Org Chart

Insights to Initiatives, Projects, & Budgets

Decision Maker Contact Info

Contact Info